Lexicon Pharmaceuticals has been upgraded to a Buy rating due to several upcoming catalysts in its drug pipeline. The company plans to resubmit its New Drug Application (NDA) for ZYNQUISTA in treating Type 1 Diabetes by Q4 2026, pending safety data from the STENO1 study. Additionally, top-line results from the phase 3 SONATA-HCM trial for sotagliflozin in hypertrophic cardiomyopathy are expected in Q1 2027. A partnership with Novo Nordisk on LX9851 for obesity could bring up to $1 billion in milestone payments, though financial risks remain. These developments position Lexicon as a promising biotech investment opportunity.
Lexicon Pharmaceuticals' pipeline developments come as context from Pluang's Health sector data. For readers following health stocks, here is Pluang's market snapshot as of Oct 01, 2026 01:11 WIB: out of 100 priced US health stocks, 48 rose and 52 fell. Heron Therapeutics Inc (HRTX) gained 5.58% to USD 0.33 with a typical hold time of 35 days, contrasting with Moderna, Inc. (MRNA) which dropped 5.52% to USD 192.23 and a longer hold time of 59 days. Hims and Hers Health Inc (HIMS) rose 5.47% to USD 30.27, showing strong buy interest at 99% buy order activity.
In September 2026, Tesla's stock rose modestly by about 1.1%, outperforming its Detroit rivals Ford and General Motors, which saw declines of 13.4% and 10.8% respectively. This divergence highlights Tesla's resilience amid a tough month for consumer ...
A class action lawsuit has been filed against Qfin Holdings, Inc. by investors who bought Qfin securities between March 18 and August 25, 2026. The lawsuit alleges that Qfin overstated its business stability and downplayed the negative impact of regu...
Jefferies analysts project that Shopify's pursuit of nationwide money transmitter licenses could increase its gross profit by about 2% and operating income by 5% in 2028. These licenses would allow Shopify to directly manage merchant funds, enhancing...
Neogen Corporation's stock fell as much as 7.22% following an FDA warning about its recalled equine product HYCOAT, which was found to contain multiple fungal species. The contamination reportedly affected nearly 100 horses and caused at least 20 dea...
XRP trades around $1.51, holding steady near the $1.50 mark since late September. A key event is the shareholder vote in New York on the merger creating Evernorth, a company holding 473 million XRP, which would list on Nasdaq under ticker XRPN. This ...
